{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["6(1)"],"submitter":["Suschak JJ"],"funding":["Military Infectious Disease Research Program"],"pubmed_abstract":["Crimean-Congo hemorrhagic fever virus (CCHFV) is a tick-borne virus that causes severe hemorrhagic fever disease in humans. Currently, no licensed CCHF vaccines exist, and the protective epitopes remain unclear. Previously, we tested a DNA vaccine expressing the M-segment glycoprotein precursor gene of the laboratory CCHFV strain IbAr 10200 (CCHFV-M<sub>10200</sub>). CCHFV-M<sub>10200</sub> provided >60% protection against homologous CCHFV-IbAr 10200 challenge in mice. Here, we report that increasing the dose of CCHFV-M<sub>10200</sub> provides complete protection from homologous CCHFV challenge in mice, and significant (80%) protection from challenge with the clinically relevant heterologous strain CCHFV-Afg09-2990. We also report complete protection from CCHFV-Afg09-2990 challenge follow"],"journal":["NPJ vaccines"],"pagination":["31"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7925670"],"repository":["biostudies-literature"],"pubmed_title":["A CCHFV DNA vaccine protects against heterologous challenge and establishes GP38 as immunorelevant in mice."],"pmcid":["PMC7925670"],"pubmed_authors":["Golden JW","Fitzpatrick CJ","Shoemaker CJ","Garrison AR","Suschak JJ","Schmaljohn CS","Badger CV"],"additional_accession":[]},"is_claimable":false,"name":"A CCHFV DNA vaccine protects against heterologous challenge and establishes GP38 as immunorelevant in mice.","description":"Crimean-Congo hemorrhagic fever virus (CCHFV) is a tick-borne virus that causes severe hemorrhagic fever disease in humans. Currently, no licensed CCHF vaccines exist, and the protective epitopes remain unclear. Previously, we tested a DNA vaccine expressing the M-segment glycoprotein precursor gene of the laboratory CCHFV strain IbAr 10200 (CCHFV-M<sub>10200</sub>). CCHFV-M<sub>10200</sub> provided >60% protection against homologous CCHFV-IbAr 10200 challenge in mice. Here, we report that increasing the dose of CCHFV-M<sub>10200</sub> provides complete protection from homologous CCHFV challenge in mice, and significant (80%) protection from challenge with the clinically relevant heterologous strain CCHFV-Afg09-2990. We also report complete protection from CCHFV-Afg09-2990 challenge follow","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Mar","modification":"2026-04-16T15:03:49.609Z","creation":"2025-02-19T02:14:40.47Z"},"accession":"S-EPMC7925670","cross_references":{"pubmed":["33654101"],"doi":["10.1038/s41541-021-00293-9"]}}